OMER
Omeros Corp
NASDAQ · Pharmaceuticals
$11.23
+0.49 (+4.56%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 179.53M | 176.40M | 195.82M |
| Net Income | 39.25M | 28.13M | 36.61M |
| EPS | — | — | — |
| Profit Margin | 21.9% | 16.0% | 18.7% |
| Rev Growth | -2.9% | +12.2% | +10.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 235.40M | 230.21M | 255.32M |
| Total Equity | 332.20M | 318.14M | 344.37M |
| D/E Ratio | 0.71 | 0.72 | 0.74 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 43.74M | 50.64M | 56.07M |
| Free Cash Flow | 39.04M | 39.72M | 27.68M |